Overview

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
0
Participant gender:
All
Summary
This clinical trial studies how well 18F-fluoromisonidazole ([18F]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. [18F]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by [18F]FMISO is picked up by a PET scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sanjiv Sam Gambhir
Collaborator:
National Cancer Institute (NCI)
Treatments:
Misonidazole
Criteria
Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Histopathologic or imaging and clinical features of tumor(s) diagnostic for
hepatocellular carcinoma with at least one tumor >= 1.5 cm; imaging features
diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and
Data System (LIRADS) 4 or greater

- Total bilirubin < 3.0

- Child Pugh A or B

- Tumor amenable to transcatheter arterial embolization

- Able to provide informed consent

Exclusion Criteria:

- Uncontrolled large ascites

- Main or segmental portal vein thrombosis

- Locoregional treatment of hepatocellular carcinoma within the prior 3 months or
chemotherapy within the previous 3 months

- Inability or contraindication to undergo transcatheter arterial embolization

- Inability to lay flat for at least 2 consecutive hours

- Severe acute illness

- Uncontrolled chronic illness such as hypertension, diabetes, or heart failure

- Contraindication to CT or MRI contrast

- Pregnancy